- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pembrolizumab Misses PFS Endpoint in Relapsed Malignant Pleural Mesothelioma
September 30th 2019, 9:40pm
Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.
Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer
September 30th 2019, 6:42pm
A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.
Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer
September 30th 2019, 6:34pm
The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.
ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma
September 30th 2019, 6:30pm
Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.
Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC
September 30th 2019, 6:30pm
Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.
Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers
September 29th 2019, 10:05pm
The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.
Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer
September 29th 2019, 9:45pm
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.
Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer
September 29th 2019, 9:45pm
ESMO Congress: Gynecologic Cancers
Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
September 29th 2019, 9:36pm
ESMO Congress: Head and Neck Cancer
The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.
PD-L1 Assays Demonstrate
September 29th 2019, 8:45pm
An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.
Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer
September 29th 2019, 8:16pm
The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.
Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer
September 29th 2019, 7:30pm
With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.
Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer
September 29th 2019, 6:59pm
Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.
Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer
September 29th 2019, 6:52pm
The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
September 29th 2019, 6:35pm
Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.
Trilaciclib Delivers "Unexpected" Survival Boost in TNBC
September 29th 2019, 4:23pm
The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.
Adding Atezolizumab May Improve Outcomes in HER2+ Breast Cancer With PD-L1 Expression
September 28th 2019, 10:30pm
A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.
Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC
September 28th 2019, 9:45pm
Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma
September 28th 2019, 9:42pm
Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.
Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer
September 28th 2019, 8:58pm
More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).